pigmented patch over chest since birth measuring 20.5 cm in length [ Figure 1 ]. Similar lesions were also present on thighs and lumbosacral region.
INTRODUCTION
C ongenital melanocytic nevi are defined as benign nevomelanocytic proliferations present at birth. Congenital melanocytic nevi occur in approximately 1-2% of newborns with a female predominance and are usually classified according to their size. [1] Giant congenital melanocytic nevus (GCMN) are even rare (1 in 200,000-500,000) [1] and they are most simply defined as melanocytic nevi that are >20 cm in largest dimension. They are usually deeply pigmented, covered with a moderate growth of hair and often there are many scattered satellite lesions associated with them. Malignant melanoma (MM) and malignant neuroectodermal tumors might develop in these lesions.
Congenital nevi can exhibit distinctive histologic features on biopsy that can help in differentiating them from common acquired nevi. [1] Here we are presenting a rare case of GCMN in a 3-day-old female child.
CASE REPORT
Three days old female child with an uneventful antenatal history, presented with an extensive Immunohistochemically S-100 was showing diffuse and intense positivity in nevus cells [ Figure 2 ].
DISCUSSION
Congenital melanocytic nevi is neurocristopathy (a disorder of the development of the embryonic neural crest), with unknown etiology. Majority of congenital melanocytic nevi, develop during first trimester of pregnancy. Vast majority are sporadic, but familial cases are also reported. [2] Congenital melanocytic nevi vary greatly in size, macroscopic appearance, and histology. There is a practical need to subdivide congenital nevi according to size, since size differences have a direct bearing on cosmetic, therapeutic options, and probably on the chance of malignant transformation. [3] They are classified according to their sizes as small (<1.5 cm), medium (1.5-19.9 cm) and large or giant (≥20 cm) congenital melanocytic nevus (giant pigmented nevus, giant cerebriform nevus, garment nevus, bathing trunk nevus, etc). The incidence of the small naevi is one in 100 births, that of the medium naevi is 6 in 1000 births, and that of GCMN, which are larger than 20 cm in diameter is 1/500,000 newborns. [4] The best parameters distinguishing a congenital nevus from an acquired nevus are its presence at birth and its larger size. The histologic appearance of giant congenital nevi differs from that of acquired nevi in terms of their greater size and depth, and in the involvement of skin appendages. The extension of nevus cells into the upper reticular dermis, within skin appendages, and angiocentric distribution is quite characteristic of congenital nevi. [5] The culture of melanocytes from such lesions showed chromosomal rearrangements which involved the chromosomal regions 1p, 12p, and 19p. Researchers think that a body protein which is called hepatocyte growth factor/scatter factor seems to be responsible for encouraging the neuroectodermal cells to develop, migrate, and scatter. It seems that either too much or a wrong type of this protein in some cells, develop extra pigment, and abnormal skin cells which are called nevus cells. These cells scatter around and so, we have naevi scattered all over the body. [4] While the association between GCMN and MM has been established beyond any doubt, the exact magnitude of the risk is still unknown. The lifetime risk of melanoma for patients with giant congenital nevi has been reported to range from 5% to 40%. [6] Management decisions of congenital melanocytic nevi, regardless of their size, should take into consideration the perceived risk of melanoma, the patient's age, the cosmetic outcome, the surgical complexity, and the risk of anesthesia. [6, 7] The risk of developing melanoma in giant congenital nevi appears to be greatest in the first decade of life. [6, 8] Intervention, if recommended, must start early in life. The options for management of giant congenital nevi include staged excision with grafting, dermabrasion, curettage, Q-switched ruby laser, and simply a close observation. [9] All patients with GCMN should be screened periodically for MM and neurocutaneous melanocytosis. Visual inspection can be facilitated by obtaining baseline images to use for comparison, which may help in the detection of subtle focal changes indicative of early Cutaneous Melanoma. [9] 
